Can I Take Melatonin with Jardiance (Empagliflozin)?

What Is the Interaction Between Melatonin and Jardiance?

The interaction between melatonin and empagliflozin is pharmacodynamic, not pharmacokinetic. Empagliflozin is metabolized primarily through UGT2B7 and UGT1A3 glucuronidation, with no meaningful involvement of CYP enzymes, so melatonin, which is metabolized by CYP1A2, does not alter empagliflozin blood levels [1][2]. The concern is about opposing effects on blood glucose control.

How Empagliflozin Lowers Blood Glucose

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing urinary excretion of roughly 70 to 90 grams of glucose per day in people with type 2 diabetes [1]. This mechanism does not depend on insulin secretion or insulin sensitivity. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin 10 mg or 25 mg reduced HbA1c by approximately 0.5 to 0.6 percentage points versus placebo at 206 weeks, while also cutting cardiovascular death by 38% (hazard ratio 0.62, 95% CI 0.49 to 0.77, P<0.001) [3].

How Melatonin Affects Glucose Metabolism

Melatonin acts on MT1 and MT2 receptors expressed on pancreatic beta cells. Activation of these receptors reduces cyclic AMP (cAMP) and cyclic GMP (cGMP) signaling, which suppresses glucose-stimulated insulin secretion [4]. A Mendelian randomization study published in Nature Genetics (N=approximately 115,000 participants) showed that carriers of a gain-of-function variant in MTNR1B, the gene encoding MT2, had 17% higher fasting glucose and a 20% higher risk of developing type 2 diabetes [5]. This genetic data support a causal role for melatonin receptor signaling in glucose homeostasis.

A 2013 randomized crossover study (N=36 healthy women) by Rubio-Sastre et al. Found that 5 mg of oral melatonin taken before a glucose tolerance test produced a statistically significant reduction in insulin secretion and a corresponding increase in glucose area under the curve (P<0.05) compared with placebo [6]. The effect was larger in MTNR1B variant carriers.

Why the Combination Still Has a Low Absolute Risk

Because empagliflozin lowers glucose through an insulin-independent route, even partial suppression of insulin secretion by melatonin does not completely negate its effect. People taking both agents are unlikely to experience dangerous hypoglycemia from melatonin alone. The greater risk is modest hyperglycemia, particularly elevated fasting glucose on the morning after taking melatonin at doses above 3 mg.

Is There a Pharmacokinetic Drug Interaction?

No clinically significant pharmacokinetic interaction has been identified between melatonin and empagliflozin. Understanding why requires a brief look at both drugs' metabolic pathways.

Empagliflozin Metabolism

Empagliflozin is primarily glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 into three inactive glucuronide metabolites [2]. The FDA prescribing information for Jardiance notes no clinically relevant interactions with CYP inhibitors or inducers [2]. Renal excretion of unchanged drug accounts for roughly 26.7% of the dose.

Melatonin Metabolism

Melatonin is predominantly metabolized by CYP1A2 to 6-sulphatoxymelatonin in the liver, with a secondary pathway through CYP1A1 [7]. Because empagliflozin does not inhibit or induce CYP1A2, it does not alter melatonin clearance. Conversely, melatonin at physiological or even pharmacological doses has not been shown to inhibit UGT enzymes to a clinically relevant degree [7].

The conclusion is straightforward: these two agents do not compete for the same metabolic enzymes, and neither significantly changes the plasma concentration of the other.

What Does the Evidence Say About Melatonin Dose and Blood Sugar?

Dose matters considerably here. Most adverse glucose data come from studies using 5 mg or more, while low-dose melatonin (0.5 to 3 mg) appears to carry far less risk.

Low-Dose Melatonin (0.5 to 3 mg)

Physiological nighttime melatonin levels peak at roughly 100 to 200 pg/mL. A 0.5 mg oral dose raises plasma melatonin to approximately 500 to 1,000 pg/mL, a level still within a broadly physiological range [8]. A 2022 meta-analysis in Nutrients (22 randomized controlled trials, N=1,376 participants with metabolic conditions) found that melatonin supplementation at doses of 2 to 10 mg had no statistically significant effect on fasting blood glucose overall, though the subgroup analysis showed a trend toward increased fasting glucose at doses above 5 mg [8]. People already on SGLT2 inhibitors were not separately analyzed in that meta-analysis, which is a meaningful data gap.

Higher Doses (5 mg and Above)

The Rubio-Sastre crossover trial cited above used 5 mg and found a significant acute impairment in oral glucose tolerance [6]. Pharmacies in the United States routinely stock 5 mg, 10 mg, and even 20 mg melatonin tablets, doses that far exceed what the sleep literature supports as effective. A 2022 narrative review in the Journal of Pineal Research noted that "a dose of 0.5 mg is sufficient to shift circadian phase and promote sleep onset in most adults, making doses above 3 mg pharmacologically unnecessary for sleep purposes" [9].

The MTNR1B Variant Consideration

Approximately 30% of people of European descent carry at least one copy of the rs10830963 risk allele in MTNR1B [5]. These individuals show exaggerated insulin-suppression responses to exogenous melatonin. Genetic testing for this variant is not standard clinical practice, but it is worth knowing that some Jardiance users may be inherently more sensitive to melatonin-driven glucose disruption.

Empagliflozin's Broader Indications and Why This Matters

Empagliflozin is FDA-approved for three distinct indications, and the glucose-interaction concern is not equally relevant across all three.

Type 2 Diabetes

In type 2 diabetes, HbA1c control is the primary metabolic target. Melatonin-driven fasting hyperglycemia could blunt the expected HbA1c reduction from empagliflozin, potentially requiring dose adjustments or additional agents. The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% (HR 0.86, 95% CI 0.74 to 0.99, P=0.04 for superiority) [3]. Suboptimal glucose control in the context of sleep disturbance could erode some of those cardiovascular gains.

Heart Failure

In the EMPEROR-Reduced trial (N=3,730), empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for worsening heart failure by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) [10]. This benefit is largely independent of HbA1c. Patients with heart failure who use melatonin for sleep disturbance, which is common in this population, are less likely to experience glucose-related harm from the combination because empagliflozin's cardiac benefits are not glucose-mediated. Still, glucose monitoring remains prudent.

Chronic Kidney Disease

The EMPA-KIDNEY trial (N=6,609) showed that empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) in patients with CKD, including many without diabetes [11]. In non-diabetic CKD patients on Jardiance, melatonin's glucose effects are even less clinically significant because blood glucose control is not the treatment goal.

Practical Guidance: Taking Melatonin While on Jardiance

The following framework reflects HealthRX clinical team recommendations based on current evidence. It is intended to guide patient-provider conversations, not replace individualized medical advice.

Step 1: Confirm the Reason for Melatonin Use

Melatonin is appropriate for circadian rhythm disruption (shift work, jet lag) and mild insomnia with a sleep-onset component. Chronic insomnia is better addressed with cognitive behavioral therapy for insomnia (CBT-I), which carries no glucose effects whatsoever [12]. If melatonin is truly needed, proceed to dose selection.

Step 2: Select the Lowest Effective Dose

Start at 0.5 mg. Most people with sleep-onset difficulty respond at 0.5 to 1 mg taken 30 to 60 minutes before the intended sleep time [8][9]. Doses above 3 mg offer no additional sleep benefit for most adults and carry the greater glucose risk documented in the literature. Avoid 5 mg, 10 mg, or 20 mg products unless your prescriber has specifically instructed otherwise.

Step 3: Check Fasting Glucose More Frequently for the First Two Weeks

If you use a glucometer, check fasting glucose each morning for 14 days after starting melatonin. A consistent rise of more than 20 mg/dL above your personal baseline warrants a call to your prescriber. Continuous glucose monitor (CGM) users will see this pattern clearly in overnight and morning glucose trends.

Step 4: Take Empagliflozin at a Consistent Time

Jardiance is typically taken once daily in the morning with or without food [2]. Melatonin is taken at night. The 12-plus-hour separation means any acute glucose effects of melatonin occur during the nighttime window and may affect the morning fasting glucose reading before the next empagliflozin dose. This timing actually allows your glucose monitor to capture the melatonin effect most clearly.

Step 5: Report Any Change in HbA1c Trend

At your next lab visit, compare HbA1c with the value from before you started melatonin. A rise of 0.3 percentage points or more that is not explained by diet or activity changes should prompt a conversation about whether continued melatonin use is worthwhile.

What Other Sleep Aids Are Compatible with Jardiance?

Melatonin is one option among several. Here is a brief comparison in the context of empagliflozin use.

Doxylamine and Diphenhydramine (OTC Antihistamines)

Both agents cause sedation through histamine H1 blockade. Neither has a known pharmacokinetic interaction with empagliflozin, and neither directly alters glucose metabolism through insulin secretion pathways. However, both can cause next-day sedation, and diphenhydramine is listed on the American Geriatrics Society Beers Criteria as a drug to avoid in older adults [13]. Their anticholinergic effects are also relevant for patients with bladder symptoms, which are already a concern with SGLT2 inhibitors due to increased urinary frequency.

Magnesium Glycinate

Magnesium has modest evidence for improving sleep quality. A 2012 double-blind placebo-controlled trial (N=46 older adults) found that 500 mg of magnesium daily improved sleep efficiency and early morning awakening scores versus placebo [14]. Magnesium does not significantly affect CYP or UGT enzyme activity, and no interaction with empagliflozin is expected. Some patients with CKD on empagliflozin may need to monitor serum magnesium levels independently of melatonin or sleep aid use.

Prescription Options

Suvorexant (Belsomra) and lemborexant (Dayvigo), both orexin receptor antagonists, are metabolized by CYP3A4 and do not interact with empagliflozin's UGT pathway. Neither has been shown to impair insulin secretion. These remain prescription-only options but may be preferable for people with type 2 diabetes who have chronic insomnia and are concerned about glucose effects.

What Do Current Guidelines Say?

The American Diabetes Association (ADA) 2024 Standards of Care in Diabetes state that clinicians should "regularly review all prescription medications, over-the-counter medications, and supplements" in patients with diabetes, noting that some supplements may affect glycemic control [15]. The ADA does not specifically list melatonin as contraindicated with any diabetes drug class but does recommend glucose monitoring when patients add new supplements.

The 2023 ACC/AHA Guideline for the Diagnosis and Treatment of Heart Failure notes that SGLT2 inhibitors are a Class I recommendation (Level of Evidence A) for patients with HFrEF to reduce hospitalization and cardiovascular mortality, and advises clinicians to review all patient supplements for potential interactions before initiating therapy [16].

No published guideline currently categorizes the melatonin-empagliflozin combination as contraindicated. The interaction is best described as a "monitor" rating rather than an "avoid" rating, consistent with how pharmacist databases such as Lexicomp and Clinical Pharmacology classify moderate-concern supplement-drug pairs.

Special Populations

Older Adults

People aged 65 and older frequently use both SGLT2 inhibitors and melatonin. Older adults may have reduced CYP1A2 activity, which can extend melatonin's half-life and prolong any glucose effects into the following morning [7]. Starting at 0.5 mg rather than 1 mg is especially prudent in this group.

Patients with Hepatic Impairment

Melatonin clearance depends on hepatic CYP1A2. In patients with liver disease, melatonin's half-life may be substantially longer than the usual 40 to 50 minutes. Empagliflozin dose adjustment is not required for mild or moderate hepatic impairment per the FDA label, but melatonin use in these patients should be minimized [2].

Patients with Type 2 Diabetes and MTNR1B Risk Variants

As described above, roughly 30% of the European-ancestry population carries an MT2 gain-of-function variant that amplifies melatonin's insulin-suppressing effect [5]. These individuals may experience disproportionate fasting glucose increases from even modest melatonin doses. Genetic panels that include MTNR1B are not yet standard of care, but direct-to-consumer tests (such as 23andMe) do report this variant.